Technology

Allakos

$132.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$3.70 (+2.88%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Allakos and other stocks, options, and ETFs commission-free!

About ALLK

Allakos Inc. Common Stock, also called Allakos, is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA. The listed name for ALLK is Allakos Inc. Common Stock.

CEO
Robert Alexander
Employees
90
Headquarters
Redwood City, California
Founded
2012
Market Cap
6.98B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
300.60K
High Today
$133.54
Low Today
$126.35
Open Price
$127.59
Volume
285.16K
52 Week High
$157.96
52 Week Low
$41.61

Collections

ALLK Earnings

-$0.86
-$0.57
-$0.29
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, Pre-Market

You May Also Like

FIII
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure